scholarly journals MA 15.08 Safety and Efficacy of Osimertinib in Treating an EGFR-Mutant Lung Cancer Patient with a Germline EGFR T790M Mutation

2017 ◽  
Vol 12 (11) ◽  
pp. S1863-S1864
Author(s):  
W. Ma ◽  
J. Gong ◽  
J. Shan ◽  
D. Lewis ◽  
W. Xiao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patient ◽  
Lung Cancer Patient ◽  
T790m Mutation ◽  
Safety And Efficacy ◽  
Egfr Mutant ◽  
Egfr T790m

Rapid clearance of circulating tumor DNA during treatment with AZD9291 of a lung cancer patient presenting the resistance EGFR T790M mutation

Lung Cancer ◽  
2016 ◽  
Vol 91 ◽  
pp. 73-74 ◽  
Author(s):  
Audrey Vallée ◽  
Clarisse Audigier-Valette ◽  
Guillaume Herbreteau ◽  
Julien Merrien ◽  
Laurent Tessonnier ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patient ◽  
Lung Cancer Patient ◽  
Circulating Tumor Dna ◽  
T790m Mutation ◽  
Rapid Clearance ◽  
Tumor Dna ◽  
Egfr T790m

scholarly journals Case Report of Non-small Cell Lung Cancer Patient with EGFR T790M Mutation Treated with Th ird Generation Inhibitor

2019 ◽  
Vol 71 ◽  
pp. 49-51
Author(s):  
Dinesh Chandra Doval ◽  
Rupal Tripathi ◽  
Kumardeep Dutta Choudhury ◽  
Ajay Sharma ◽  
Ullas Batra ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patient ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Lung Cancer Patient ◽  
Growth Factor Receptor ◽  
Small Cell ◽  
Small Cell Lung ◽  
T790m Mutation ◽  
Egfr T790m

Lung cancer treatment based on the molecular classifi cation of the tumor has paved the way for multiple lines of targeted treatment, even though the development of resistance remains a major cause of concern. Epidermal growth factor receptor (EGFR) remains the poster boy for the use of targeted therapy, and the presence/absence of mutations in this gene has led to the development of inhibitors targeting specifi c mutations. We present the case of an advanced non-small cell lung cancer patient with EGFR T790M mutation treated with Osimertinib, a third-generation inhibitor.

Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient

2018 ◽  
Vol 38 (10) ◽  
pp. 983-987 ◽  
Author(s):  
Giulio Metro ◽  
Sara Baglivo ◽  
Annamaria Siggillino ◽  
Vienna Ludovini ◽  
Rita Chiari ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patient ◽  
Lung Cancer Patient ◽  
Egfr T790m

Clinical Likelihood of Sporadic Primary EGFR T790M Mutation in EGFR-Mutant Lung Cancer

2015 ◽  
Vol 16 (1) ◽  
pp. 46-50 ◽  
Author(s):  
Youngjoo Lee ◽  
Geon Kook Lee ◽  
Jung-Ah Hwang ◽  
Tak Yun ◽  
Heung Tae Kim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
T790m Mutation ◽  
Egfr Mutant ◽  
Egfr T790m

scholarly journals A Case of Delayed Diagnostic Pulmonary Tuberculosis during Targeted Therapy in an EGFR Mutant Non-Small Cell Lung Cancer Patient

2021 ◽  
pp. 659-663
Author(s):  
Caibao Jin ◽  
Bin Yang
Keyword(s):  
Lung Cancer ◽  
Pulmonary Tuberculosis ◽  
Cancer Patient ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Lung Cancer Patient ◽  
Small Cell ◽  
Small Cell Lung ◽  
Pulmonary Tb ◽  
Egfr Mutant

The coexistence of lung cancer and pulmonary tuberculosis (TB) is rare, and the clinical and radiological features are always similar between lung cancer and pulmonary TB. In the present case, a non-small cell lung cancer patient with an epidermal growth factor receptor (EGFR)-sensitive mutation was diagnosed with pulmonary TB during the treatment of tyrosine kinase inhibitor (TKI) because of the discrepant and confusing responses among different lesions. Therefore, we should combine clinical and radiological characteristics with pathological and microbiological tests to confirm the diagnosis of TB or lung cancer. It is a safe and selectable therapeutic strategy to treat EGFR mutant lung cancer patients with active TB using anti-TB medications and TKIs simultaneously.

Sign in / Sign up

Export Citation Format

Share Document